
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Philadelphia - The human body is constantly under attack from bacteria and viruses living in our environment. When we present with clinical infections, it is the direct result of our immune system's incapability of successfully protecting us from these microbes. To achieve a better understanding of skin infections, one must try to better understand the human body's defense system, as well as the microbial virulence system.